Ir para o conteúdo principal

Eterna Therapeutics (NASDAQ: ERNA) — Perfil da empresa, notícias e dados financeiros

Logo de Eterna Therapeutics
ERNA Eterna Therapeutics
Eterna Therapeutics primary media
Perfil da empresa

Eterna Therapeutics

Eterna Therapeutics (NASDAQ:ETRN) is a biotechnology firm that focuses on the development and innovation of therapies aimed at treating and potentially curing a variety of diseases. At the heart of their operations is a commitment to research and development, through which they are currently working on several promising projects, including advanced gene editing techniques. These initiatives highlight the company's objective to push the boundaries of medicine and provide groundbreaking solutions for patients worldwide. Eterna Therapeutics is dedicated to advancing healthcare and improving the lives of patients through scientific excellence and innovative treatments.

Resumo

Public USParticipação acionária
1984Ano de fundação
8Funcionários
New York, United StatesSede
Carregando mapa...
Presença global

Operações

Todos os locais
New York City, US

Produtos e/ou serviços de Eterna Therapeutics

  • mRNA platform technology aimed at developing vaccines and therapeutics.
  • Gene editing tools for precision medicine in genetic disorders.
  • In vivo delivery systems for targeted gene therapy applications.
  • Collaboration on cancer immunotherapy treatments leveraging mRNA technology.
  • Partnerships for the development of rare disease treatments using gene therapy.
  • Research on aging and degenerative disease intervention through novel mRNA applications.

equipe executiva do Eterna Therapeutics

  • Sanjeev LutherCEO, President & Director
  • Mark J. KeeleyChief Financial Officer
  • Deborah Vee WildHead of CMC & Operations
  • Robert Hamilton PierceChief Scientific Officer
  • Dorothy J. ClarkeGeneral Counsel

Principais indicadores financeiros

Resultados divulgados pela Eterna Therapeutics, em USD.

Cap. de mercado
3,2 mi
Receita (TTM)
1 mil
P/L
—
LPA (diluído, TTM)
-13.6
Dividend yield
—
Margem de lucro
0.0%
Receita e lucro anuais da Eterna Therapeutics
Fim do ano fiscalReceitaResultado operacionalLucro líquido
0-9,3 mi-14,1 mi
582 mil-15,7 mi-44,5 mi
68 mil-21,1 mi-21,7 mi
0-33,2 mi-24,6 mi